U.S. markets close in 4 hours 16 minutes
  • S&P 500

    4,359.23
    -83.88 (-1.89%)
     
  • Dow 30

    34,386.63
    -482.74 (-1.38%)
     
  • Nasdaq

    14,581.74
    -388.23 (-2.59%)
     
  • Russell 2000

    2,244.05
    -36.96 (-1.62%)
     
  • Crude Oil

    75.06
    -0.39 (-0.52%)
     
  • Gold

    1,740.30
    -11.70 (-0.67%)
     
  • Silver

    22.52
    -0.17 (-0.74%)
     
  • EUR/USD

    1.1685
    -0.0016 (-0.14%)
     
  • 10-Yr Bond

    1.5220
    +0.0380 (+2.56%)
     
  • GBP/USD

    1.3538
    -0.0166 (-1.21%)
     
  • USD/JPY

    111.3150
    +0.3370 (+0.30%)
     
  • BTC-USD

    41,631.81
    -1,489.99 (-3.46%)
     
  • CMC Crypto 200

    1,030.49
    -26.66 (-2.52%)
     
  • FTSE 100

    7,030.73
    -32.67 (-0.46%)
     
  • Nikkei 225

    30,183.96
    -56.10 (-0.19%)
     

MediciNova To Test Ibudilast In BARDA's Validated Mouse Model Of Chlorine-Induced Pulmonary Injury

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • MediciNova Inc (NASDAQ: MNOV) will conduct a mouse study to investigate the efficacy of MN-166 (ibudilast) in a murine model of chlorine-induced lung injury and lethality.

  • After mice are exposed to chlorine gas and treated with MN-166 (ibudilast) or control, the study will evaluate survival, clinical outcomes, body weights, lung weights, and upper respiratory tract histopathology.

  • This mouse study is a step to repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage.

  • This project is federally funded in part by the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA).

  • Last week, the company garnered headlines after announcing positive results from a Phase 2 trial of MN-166 in alcohol use disorder.

  • Ibudilast, relative to placebo, reduced the odds of heavy drinking across time by 45%.

  • In response, Zacks Small-Cap Research increased the stock price target to from $26.5.

  • Price Action: MNOV shares are up 4.13% at 4.29 during the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.